1
|
Conti A, Paolinelli M. A new approach in monitoring blood tests in anti-tumour necrosis factor-α therapies in psoriasis. Br J Dermatol 2024; 190:463-464. [PMID: 38092026 DOI: 10.1093/bjd/ljad490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2023] [Accepted: 11/30/2023] [Indexed: 03/16/2024]
Affiliation(s)
- Andrea Conti
- Dermatology Unit, Department of Surgery, Infermi Hospital Rimini, AUSL Romagna, Rimini, Italy
| | - Matteo Paolinelli
- Dermatology Unit, Department of Surgery, Infermi Hospital Rimini, AUSL Romagna, Rimini, Italy
| |
Collapse
|
2
|
Marani A, Gioacchini H, Paolinelli M, Bobyr I, Martina E, Radi G, Diotalallevi F, Campanati A. Pain Control during the Treatment of Primary Palmar Hyperhidrosis with Botulinum Toxin A by a Topical Application of Liposomal Lidocaine: Clinical Effectiveness. Toxins (Basel) 2024; 16:28. [PMID: 38251244 PMCID: PMC10818596 DOI: 10.3390/toxins16010028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2023] [Revised: 12/31/2023] [Accepted: 01/03/2024] [Indexed: 01/23/2024] Open
Abstract
Primary palmar hyperhidrosis (PPH) constitutes a debilitating condition that profoundly impacts the social, functional, and occupational aspects of individuals. The intradermal administration of botulinum toxin type A (BoNT-A) stands as an established therapeutic approach for PPH, albeit one frequently accompanied by considerable pain, posing challenges for patient tolerance. Our study aimed to assess the efficacy of combining cryoanalgesia spray (CA) with topical anesthesia utilizing a cream containing liposomal lidocaine at a concentration of 40 mg/g, with the objective of mitigating the pain associated with intradermal BoNT-A injection for PPH treatment. Nineteen participants, aged ≥18 years and afflicted with severe PPH, were enrolled in a double-blind randomized vehicle-controlled trial. Patient-perceived pain during the procedure was quantified using the Numeric Rating Scale (NRS). Statistical analysis was applied to the collected data. The combination of CA and the topical application of liposomal lidocaine during BoNT-A treatment for PPH resulted in diminished pain compared to CA alone and the combination of CA with the application of a basic cream. Topical anesthesia through the application of a liposomal lidocaine-containing cream emerged as a facile, secure, and efficacious approach for alleviating the pain associated with intradermal BoNT-A injection in PPH treatment. Furthermore, it demonstrated compatibility with CA, thereby offering a comprehensive strategy for pain management during BoNT-A administration.
Collapse
Affiliation(s)
- Andrea Marani
- Clinic of Dermatology, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, 60126 Ancona, Italy; (A.M.); (H.G.); (I.B.); (E.M.); (G.R.); (F.D.)
| | - Helena Gioacchini
- Clinic of Dermatology, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, 60126 Ancona, Italy; (A.M.); (H.G.); (I.B.); (E.M.); (G.R.); (F.D.)
| | - Matteo Paolinelli
- Dermatology Unit, “Infermi” Hospital of Rimini, 47900 Rimini, Italy;
| | - Ivan Bobyr
- Clinic of Dermatology, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, 60126 Ancona, Italy; (A.M.); (H.G.); (I.B.); (E.M.); (G.R.); (F.D.)
| | - Emanuela Martina
- Clinic of Dermatology, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, 60126 Ancona, Italy; (A.M.); (H.G.); (I.B.); (E.M.); (G.R.); (F.D.)
| | - Giulia Radi
- Clinic of Dermatology, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, 60126 Ancona, Italy; (A.M.); (H.G.); (I.B.); (E.M.); (G.R.); (F.D.)
| | - Federico Diotalallevi
- Clinic of Dermatology, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, 60126 Ancona, Italy; (A.M.); (H.G.); (I.B.); (E.M.); (G.R.); (F.D.)
| | - Anna Campanati
- Clinic of Dermatology, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, 60126 Ancona, Italy; (A.M.); (H.G.); (I.B.); (E.M.); (G.R.); (F.D.)
| |
Collapse
|
3
|
Marani A, Gioacchini H, Paolinelli M, Offidani A, Campanati A. Potential drug-drug interactions with mitogen-activated protein kinase (MEK) inhibitors used to treat melanoma. Expert Opin Drug Metab Toxicol 2023; 19:555-567. [PMID: 37659065 DOI: 10.1080/17425255.2023.2255519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2023] [Revised: 08/08/2023] [Accepted: 09/01/2023] [Indexed: 09/05/2023]
Abstract
INTRODUCTION The management of patients with BRAF-mutated advanced melanoma who are undergoing targeted therapy with MEK inhibitors can be complicated by the co-administration of multiple medications, which can give rise to drug-drug interactions of clinical significance. COVERED AREAS Our review presents a comprehensive analysis of the pharmacokinetic and pharmacodynamic interactions of the three approved for advanced melanoma MEK inhibitor drugs - binimetinib, cobimetinib, and trametinib. MEDLINE (PubMed) was utilized for the literature search, comprising clinical studies, observational studies, and preclinical research. The review discusses the impact of these interactions on efficacy and safety of the treatments and differentiates between interactions supported by pharmacokinetic or pharmacodynamic mechanisms, those encountered in clinical practice, and those observed in preclinical studies. EXPERT OPINION Physicians should be aware about potential benefits, but also increased toxicity caused by drug interactions between MEK inhibitors and other drugs in the management of patients with metastatic melanoma.
Collapse
Affiliation(s)
- A Marani
- Dermatologic Clinic, Department of Clinical and Molecular Sciences, Ancona, Marche, Italy
| | - H Gioacchini
- Dermatologic Clinic, Department of Clinical and Molecular Sciences, Ancona, Marche, Italy
| | - M Paolinelli
- Dermatologic Clinic, Department of Clinical and Molecular Sciences, Ancona, Marche, Italy
| | - A Offidani
- Dermatologic Clinic, Department of Clinical and Molecular Sciences, Ancona, Marche, Italy
| | - A Campanati
- Dermatologic Clinic, Department of Clinical and Molecular Sciences, Ancona, Marche, Italy
| |
Collapse
|
4
|
Radi G, Rossi R, Diotallevi F, Giannoni M, Molinelli E, Paolinelli M, Ferrara G, Offidani A. The role of the optical super high magnification dermoscopy (O.S.H.M.D) in the management of melanocytic lesions. J Eur Acad Dermatol Venereol 2023; 37:e122-e124. [PMID: 35977047 DOI: 10.1111/jdv.18533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2022] [Accepted: 08/08/2022] [Indexed: 12/15/2022]
Affiliation(s)
- Giulia Radi
- Dermatological Clinic Department of Clinical and Molecular Sciences, Polytechnic University of the Marche Region, Ancona, Italy
| | - Renato Rossi
- Department of Dermatology, Skin Center Senigallia, Ancona, Italy
| | - Federico Diotallevi
- Dermatological Clinic Department of Clinical and Molecular Sciences, Polytechnic University of the Marche Region, Ancona, Italy
| | - Melania Giannoni
- Dermatological Clinic Department of Clinical and Molecular Sciences, Polytechnic University of the Marche Region, Ancona, Italy
| | - Elisa Molinelli
- Dermatological Clinic Department of Clinical and Molecular Sciences, Polytechnic University of the Marche Region, Ancona, Italy
| | - Matteo Paolinelli
- Dermatological Clinic Department of Clinical and Molecular Sciences, Polytechnic University of the Marche Region, Ancona, Italy
| | - Gerardo Ferrara
- Anatomic Pathology and Cytopathology Unit, Istituto Nazionale Tumori IRCCS Fondazione'G. Pascale', Naples, Italy
| | - Annamaria Offidani
- Dermatological Clinic Department of Clinical and Molecular Sciences, Polytechnic University of the Marche Region, Ancona, Italy
| |
Collapse
|
5
|
Diotallevi F, Paolinelli M, Radi G, Offidani A. Latest combination therapies in psoriasis: Narrative review of the literature. Dermatol Ther 2022; 35:e15759. [PMID: 35959523 PMCID: PMC9786636 DOI: 10.1111/dth.15759] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2022] [Revised: 06/29/2022] [Accepted: 08/07/2022] [Indexed: 12/30/2022]
Abstract
Biological therapies revolutionized the treatment of many chronic inflammatory skin diseases, first of all psoriasis, thanks to their high efficacy and the reduced number of side effects. However, the use of a single biologic drug does not always provide complete control of the disease or associated comorbidities over time. The first biological drugs used for the treatment of psoriasis, tumor necrosis factor alpha inhibitors, have long been used in combination with traditional topical and systemic therapies to induce a complete remission of the disease that could not be achieved with innovative drug alone. Even with the advent of new biological therapies with more precise molecular targets, the challenge of using combination therapies remained. Psoriatic patients often have major comorbidities, such as arthritis, inflammatory bowel disease, uveitis or have other concomitant conditions such as chronic spontaneous urticaria and atopic dermatitis, which may require different biologic treatments than those indicated in psoriasis. The objective of this article is, through a comprehensive revision of the literature, to analyze in which cases the use of the combination of the latest therapies for psoriasis may be useful.
Collapse
Affiliation(s)
- Federico Diotallevi
- Dermatological Clinic, Department of Clinical and Molecular SciencesPolytechnic University of the Marche RegionAnconaItaly
| | - Matteo Paolinelli
- Dermatological Clinic, Department of Clinical and Molecular SciencesPolytechnic University of the Marche RegionAnconaItaly
| | - Giulia Radi
- Dermatological Clinic, Department of Clinical and Molecular SciencesPolytechnic University of the Marche RegionAnconaItaly
| | - Annamaria Offidani
- Dermatological Clinic, Department of Clinical and Molecular SciencesPolytechnic University of the Marche RegionAnconaItaly
| |
Collapse
|
6
|
Longone V, Escoriaza G, Paolinelli M, Gramaje D. First Report of Dactylonectria alcacerensis, Dactylonectria macrodidyma, and Ilyonectria liriodendri Associated with Black Foot Disease of Grapevine in Argentina. Plant Dis 2022; 106:PDIS10212346PDN. [PMID: 35100835 DOI: 10.1094/pdis-10-21-2346-pdn] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Affiliation(s)
- V Longone
- Estación Experimental Agropecuaria Mendoza, Instituto Nacional de Tecnología Agropecuaria (EEA-Mendoza-INTA), San Martín 3853, Luján de Cuyo, 5534, Mendoza, Argentina
| | - G Escoriaza
- Estación Experimental Agropecuaria Mendoza, Instituto Nacional de Tecnología Agropecuaria (EEA-Mendoza-INTA), San Martín 3853, Luján de Cuyo, 5534, Mendoza, Argentina
| | - M Paolinelli
- Estación Experimental Agropecuaria Mendoza, Instituto Nacional de Tecnología Agropecuaria (EEA-Mendoza-INTA), San Martín 3853, Luján de Cuyo, 5534, Mendoza, Argentina
| | - D Gramaje
- Instituto de Ciencias de la Vid y del Vino, Consejo Superior de Investigaciones Científicas, Universidad de la Rioja, Gobierno de La Rioja 26007 Logroño, Spain
| |
Collapse
|
7
|
Colombo D, Bianchi L, Fabbrocini G, Corrao S, Offidani A, Stingeni L, Costanzo A, Pellacani G, Peris K, Bardazzi F, Argenziano G, Ruffolo S, Dapavo P, Carrera C, Fargnoli MC, Parodi A, Romanelli M, Malagoli P, Talamonti M, Megna M, Raspanti M, Paolinelli M, Hansel K, Narcisi A, Conti A, De Simone C, Chessa MA, De Rosa A, Provenzano E, Ortoncelli M, Moltrasio C, Fidanza R, Burlando M, Tonini A, Gaiani FM, Simoni L, Ori A, Fiocchi M, Zagni E. Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study. Dermatol Ther 2021; 35:e15166. [PMID: 34676662 DOI: 10.1111/dth.15166] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2020] [Revised: 10/01/2021] [Accepted: 10/15/2021] [Indexed: 12/20/2022]
Abstract
EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional (CANOVA) study was aimed at providing real-world evidence of the effectiveness of biologics in Italian patients with moderate-severe psoriasis. It was an observational, retro-prospective cohort study conducted in 17 Italian dermatology clinics. Adult patients with moderate-severe plaque psoriasis, who started a biologic treatment between 24 weeks and 24 months before enrolment, were included. With a follow-up visit at 6 months after enrolment, each patient had at least 12 months of observation. The primary objective was to describe the clinical response rates (PASI 75) after 16/24/52 weeks from biologic treatment start. Secondary outcomes were sustained response, quality of life, and treatment satisfaction. Of the 669 eligible patients (64% males), 52% were naïve to biologics, though a mean duration of psoriasis since first diagnosis of 18.6 years (SD 13.2). The most frequently prescribed biologics were secukinumab (41%), ustekinumab (25%), TNF-inhibitors (22%) and ixekizumab (12%). PASI 75 was achieved by 86% of patients (95% CI: 82%-89%) at 16 weeks, 90% (87%-93%) at 24 weeks, and 91% (89%-94%) at 52 weeks. Patients achieving PASI 90 and PASI 100 at 52 weeks were 75% (71%-79%) and 53% (49%-57%), respectively. Sustained PASI 75 response after 1 year from treatment start was achieved by 78% (74%-82%) of patients. Mean DLQI total score was 2.3 (SD 3.9) at enrollment and decreased at the final visit to 1.8 (3.6). A high level of treatment satisfaction was expressed by patients over the study period. This large real-world study confirms in the clinical practice the good effectiveness and acceptability of biologics in psoriasis patients.
Collapse
Affiliation(s)
| | - Luca Bianchi
- Dermatology, Policlinico Tor Vergata, Rome, Italy
| | | | | | | | - Luca Stingeni
- Dermatology Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy
| | | | | | - Ketty Peris
- Dermatology, Fondazione Policlinico Universitario A. Gemelli-IRCCS e Università Cattolica, Rome, Italy
| | | | | | - Silvana Ruffolo
- Dermatology, A.O. Cosenza Ospedale SS Annunziata, Cosenza, Italy
| | - Paolo Dapavo
- Dermatology, A.O.U. Città della Salute e della Scienza PO Molinette, Turin, Italy
| | - Carlo Carrera
- Dermatology, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - Maria Concetta Fargnoli
- Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy
| | - Aurora Parodi
- Dermatology, Clinica Dermatologica DiSSal Università di Genova/Ospedale-Policlinico San Martino IRCCS, Genoa, Italy
| | - Marco Romanelli
- Dermatology, A.O.U. Pisana Ospedale Santa Chiara, Pisa, Italy
| | | | | | | | | | | | - Katharina Hansel
- Dermatology Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy
| | | | | | - Clara De Simone
- Dermatology, Fondazione Policlinico Universitario A. Gemelli-IRCCS e Università Cattolica, Rome, Italy
| | | | - Alina De Rosa
- Dermatology Unit, University of Campania, Naples, Italy
| | | | - Michela Ortoncelli
- Dermatology, A.O.U. Città della Salute e della Scienza PO Molinette, Turin, Italy
| | - Chiara Moltrasio
- Dermatology, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - Rosaria Fidanza
- Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy
| | - Martina Burlando
- Dermatology, Clinica Dermatologica DiSSal Università di Genova/Ospedale-Policlinico San Martino IRCCS, Genoa, Italy
| | - Annalisa Tonini
- Dermatology, A.O.U. Pisana Ospedale Santa Chiara, Pisa, Italy
| | | | - Lucia Simoni
- Clinical Data Management and Statistics, MediNeos Observational Research, Modena, Italy
| | - Alessandra Ori
- Clinical Operations, MediNeos Observational Research, Modena, Italy
| | | | | |
Collapse
|
8
|
Zagni E, Bianchi L, Fabbrocini G, Corrao S, Offidani A, Stingeni L, Costanzo A, Pellacani G, Peris K, Bardazzi F, Argenziano G, Ruffolo S, Dapavo P, Carrera C, Fargnoli MC, Parodi A, Romanelli M, Malagoli P, Talamonti M, Megna M, Raspanti M, Paolinelli M, Hansel K, Narcisi A, Conti A, De Simone C, Chessa MA, De Rosa A, Provenzano E, Ortoncelli M, Moltrasio C, Fidanza R, Burlando M, Tonini A, Gaiani FM, Simoni L, Zullo A, Fiocchi M, Colombo D. A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study. BMC Health Serv Res 2021; 21:924. [PMID: 34488749 PMCID: PMC8422702 DOI: 10.1186/s12913-021-06866-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2021] [Accepted: 08/04/2021] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND Psoriasis is a chronic immune-mediated inflammatory skin disease which can also involve joints. It is often associated with burdensome comorbidities which negatively impact prognosis and quality of life (QoL). Biologic agents have been shown to be effective in controlling disease progression, but their use is associated with higher costs compared with traditional systemic treatments. The economic analysis of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: an obserVAtional longitudinal study of real-life clinical practice) study aims to assess the costs and cost-effectiveness of biologics in a real-world context in Italy. METHODS The annualised overall direct costs of moderate-to-severe plaque psoriasis management, the annualised cost of biologic drugs and the cost per responder in the Italian National Health System perspective were assessed. More specifically, the cost per response and cost per sustained response of the most prescribed biologic therapies for the treatment of moderate-to-severe plaque psoriasis within the CANOVA study were assessed using the Psoriasis Area Severity Index (PASI) at several score levels (75, 90 and 100%). RESULTS The most frequently used biologic therapies for plaque psoriasis were secukinumab, ustekinumab, adalimumab originator, and ixekizumab. Cost of biologics was the driver of expenditure, accounting for about 98% of total costs. Adalimumab originator was the biologic with the lowest cost per responder ratio (range: €7848 - €31,378), followed by secukinumab (range: €9015 - €33,419). Ustekinumab (range: €11,689 - €39,280) and ixekizumab (range: €11,092 - €34,289) ranked respectively third and fourth, in terms of cost-effectiveness ratio. As concerns the cost per sustained response analysis, secukinumab showed the lowest value observed (€21,375) over the other options, because of its high response rate (86% vs. 60-80%), which was achieved early in time. CONCLUSION Biologic therapy is a valuable asset for the treatment of moderate-to-severe plaque psoriasis. Concomitant assessment of treatment costs against the expected therapeutic response over time can provide physicians and payers additional insights which can complement the traditional risk-benefit profile assessment and drive treatment decisions.
Collapse
Affiliation(s)
- Emanuela Zagni
- Novartis Farma S.p.A, Largo Umberto Boccioni, 1, 21040, Origgio, Varese, Italy.
| | | | - Gabriella Fabbrocini
- Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| | | | - Annamaria Offidani
- Dermatology Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| | - Luca Stingeni
- Dermatology Section, Department of Medicine, University of Perugia, Perugia, Italy
| | | | - Giovanni Pellacani
- Dermatology Clinic, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, La Sapienza University of Rome, Rome, Italy
| | - Ketty Peris
- Fondazione Policlinico Universitario A. Gemelli-IRCCS and Università Cattolica, Rome, Italy
| | - Federico Bardazzi
- Dermatology, IRCCS Policlinico di S Orsola Department of Experimental, Diagnostic and Specialty Medicine (DIMES) Alma Mater Studiorum University of Bologna, Bologna, Italy
| | | | | | - Paolo Dapavo
- A.O.U. Città della Salute e della Scienza PO Molinette, Turin, Italy
| | - Carlo Carrera
- Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - Maria Concetta Fargnoli
- Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy
| | - Aurora Parodi
- Clinica Dermatologica DiSSal Università di Genova/Ospedale-Policlinico San Martino IRCCS, Genoa, Italy
| | - Marco Romanelli
- U.O. Dermatologia Universitaria - Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
| | | | | | | | | | - Matteo Paolinelli
- Dermatology Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| | - Katharina Hansel
- Dermatology Section, Department of Medicine, University of Perugia, Perugia, Italy
| | | | | | - Clara De Simone
- Fondazione Policlinico Universitario A. Gemelli-IRCCS and Università Cattolica, Rome, Italy
| | - Marco Adriano Chessa
- Dermatology, IRCCS Policlinico di S Orsola Department of Experimental, Diagnostic and Specialty Medicine (DIMES) Alma Mater Studiorum University of Bologna, Bologna, Italy
| | - Alina De Rosa
- Dermatology Unit, University of Campania, Naples, Italy
| | | | | | - Chiara Moltrasio
- Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - Rosaria Fidanza
- Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy
| | - Martina Burlando
- Clinica Dermatologica DiSSal Università di Genova/Ospedale-Policlinico San Martino IRCCS, Genoa, Italy
| | - Annalisa Tonini
- U.O. Dermatologia Universitaria - Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
| | | | | | | | - Martina Fiocchi
- Novartis Farma S.p.A, Largo Umberto Boccioni, 1, 21040, Origgio, Varese, Italy
| | - Delia Colombo
- Novartis Farma S.p.A, Largo Umberto Boccioni, 1, 21040, Origgio, Varese, Italy
| |
Collapse
|
9
|
Corazza M, Forconi R, Patrizi A, Veneziano L, Offidani A, Paolinelli M, Stingeni L, Hansel K, Foti C, Barlusconi C, Valpiani G, Morotti C, Borghi A. The use of the internet by outpatients in dermatology: a multicentric, observational and cross-sectional study on frequency, motivations and feedback. J Eur Acad Dermatol Venereol 2021; 35:e578-e582. [PMID: 33871062 DOI: 10.1111/jdv.17284] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- M Corazza
- Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, Ferrara, Italy
| | - R Forconi
- Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, Ferrara, Italy
| | - A Patrizi
- Department of Experimental, Diagnostic and Speciality Medicine (DIMES), University of Bologna, Bologna, Italy
| | - L Veneziano
- Department of Experimental, Diagnostic and Speciality Medicine (DIMES), University of Bologna, Bologna, Italy
| | - A Offidani
- Department of Clinical and Molecular Sciences, Dermatology Unit, Polytechnic Marche University, Ancona, Italy
| | - M Paolinelli
- Department of Clinical and Molecular Sciences, Dermatology Unit, Polytechnic Marche University, Ancona, Italy
| | - L Stingeni
- Dermatology Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy
| | - K Hansel
- Dermatology Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy
| | - C Foti
- Department of Biomedical Science and Human Oncology, Dermatological Clinic, University of Bari "Aldo Moro", Bari, Italy
| | - C Barlusconi
- Department of Biomedical Science and Human Oncology, Dermatological Clinic, University of Bari "Aldo Moro", Bari, Italy
| | - G Valpiani
- Research Innovation Office, S. Anna University Hospital of Ferrara, Ferrara, Italy
| | - C Morotti
- Research Innovation Office, S. Anna University Hospital of Ferrara, Ferrara, Italy
| | - A Borghi
- Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, Ferrara, Italy
| |
Collapse
|
10
|
Molinelli E, Brisigotti V, Paolinelli M, Offidani A. Novel Therapeutic Approaches and Targets for the Treatment of Neutrophilic Dermatoses, Management of Patients with Neutrophilic Dermatoses and Future Directions in the Era of Biologic Treatment. Curr Pharm Biotechnol 2021; 22:46-58. [PMID: 32359335 DOI: 10.2174/1389201021666200503050803] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2019] [Revised: 03/09/2020] [Accepted: 03/17/2020] [Indexed: 11/22/2022]
Abstract
Neutrophilic dermatoses are a heterogeneous group of inflammatory skin disorders characterized by the presence of a sterile, predominantly neutrophilic infiltrate on histopathology. Universally accepted and validated guidelines for the management of neutrophilic dermatoses do not exist, also given the paucity of randomized controlled study and high-quality data. However, the literature on the effective use of biologic therapies is rapidly expanding. This article reviews the epidemiology, clinical characteristics, histopathologic features, and management of pyoderma gangrenosum as well as Sweet's syndrome, sub-corneal pustular dermatoses and bowel-associated dermatosis arthritis syndrome. The use of biologic agents, including tumor necrosis factor α-inhibitors, anti-IL1, anti-IL-17, and IL-23 are discussed in detail.
Collapse
Affiliation(s)
- Elisa Molinelli
- Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| | - Valerio Brisigotti
- Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| | - Matteo Paolinelli
- Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| | - Annamaria Offidani
- Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| |
Collapse
|
11
|
Martina E, Diotallevi F, Bianchelli T, Paolinelli M, Offidani A. Novel Therapeutic Approaches and Targets for Treatment of Chronic Urticaria: New Insights and Promising Targets for a Challenging Disease. Curr Pharm Biotechnol 2021; 22:32-45. [PMID: 32603278 DOI: 10.2174/1389201021666200630140137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2019] [Revised: 01/29/2020] [Accepted: 04/30/2020] [Indexed: 11/22/2022]
Abstract
BACKGROUND Chronic Spontaneous Urticaria (CSU) is a disease characterized by the onset of wheals and/or angioedema over 6 weeks. The pathophysiology for CSU is very complex, involving mast cells and basophils with a multitude of inflammatory mediators. For many years the treatment of CSU has been based on the use of antihistamines, steroids and immunosuppressive agents with inconstant and frustrating results. The introduction of omalizumab, the only licensed biologic for antihistamine- refractory CSU, has changed the management of the disease. OBJECTIVE The aim of this article is to review the current state of the art of CSU, the real-life experience with omalizumab and the promising drugs that are under development. METHODS An electronic search was performed to identify studies, case reports, guidelines and reviews focused on the new targets for the treatment of chronic spontaneous urticaria, both approved or under investigation. The search was limited to articles published in peer-reviewed journals in the English Language in the PubMed database and trials registered in Clinicaltrials.gov. RESULTS Since the advent of omalizumab, the search for new therapies for chronic spontaneous urticaria has had a new impulse. Anti-IgE drugs will probably still be the cornerstone of therapy, but new targets may prove effective in syndromic urticaria or refractory cases. CONCLUSION Although omalizumab has been a breakthrough in the treatment of CSU, many patients do not completely get benefit and even require more effective treatments. Novel drugs are under investigation with promising results.
Collapse
Affiliation(s)
- Emanuela Martina
- Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| | - Federico Diotallevi
- Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| | - Tommaso Bianchelli
- Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| | - Matteo Paolinelli
- Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| | - Annamaria Offidani
- Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| |
Collapse
|
12
|
Giannoni M, Rizzetto G, Sapigni C, Paolinelli M, Tagliati C, Diotallevi F, Campanati A, Mandolesi A, Pepi L, Offidani A. Bullous Sweet’s syndrome in a patient with ulcerative colitis: a rare case report. Acta Dermatovenerologica Alpina Pannonica et Adriatica 2020. [DOI: 10.15570/actaapa.2020.31] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
13
|
Simonetti O, Diotallevi F, Campanati A, Brisigotti V, Radi G, Molinelli E, Bobyr I, Martina E, Paolinelli M, Sapigni C, Offidani A. Global coronavirus pandemic
(
SARS‐CoV
‐2):
Past
,
present
,
and future of pediatric dermatology. Dermatol Ther 2020; 33:e13767. [PMID: 32500648 PMCID: PMC7300526 DOI: 10.1111/dth.13767] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2020] [Revised: 05/29/2020] [Accepted: 06/01/2020] [Indexed: 01/08/2023]
Abstract
Two months have passed since the World Health Organization (WHO) declared the pandemic of the Coronavirus Disease 19 (COVID‐19), caused by the SARS‐CoV‐2 virus, on 11 March 2020. Medical and healthcare workers have continued to be on the frontline to defeat this disease, however, continual changes are being made to their working habits which are proving to be difficult. Although the skin is not the main target of the SARS‐CoV‐2 infection, it is strongly involved both directly and indirectly, in many aspects of dermatological disease management, and particularly in pediatric dermatology. In this manuscript, our goal was to provide a “up‐to‐date” account on this topic, through analysis of current literature and sharing our experiences during this pandemic.
Collapse
Affiliation(s)
- Oriana Simonetti
- Dermatological Clinic, Department of Clinical and Molecular Sciences Polytechnic University of the Marche Region Ancona Italy
| | - Federico Diotallevi
- Dermatological Clinic, Department of Clinical and Molecular Sciences Polytechnic University of the Marche Region Ancona Italy
| | - Anna Campanati
- Dermatological Clinic, Department of Clinical and Molecular Sciences Polytechnic University of the Marche Region Ancona Italy
| | - Valerio Brisigotti
- Dermatological Clinic, Department of Clinical and Molecular Sciences Polytechnic University of the Marche Region Ancona Italy
| | - Giulia Radi
- Dermatological Clinic, Department of Clinical and Molecular Sciences Polytechnic University of the Marche Region Ancona Italy
| | - Elisa Molinelli
- Dermatological Clinic, Department of Clinical and Molecular Sciences Polytechnic University of the Marche Region Ancona Italy
| | - Ivan Bobyr
- Dermatological Clinic, Department of Clinical and Molecular Sciences Polytechnic University of the Marche Region Ancona Italy
| | - Emanuela Martina
- Dermatological Clinic, Department of Clinical and Molecular Sciences Polytechnic University of the Marche Region Ancona Italy
| | - Matteo Paolinelli
- Dermatological Clinic, Department of Clinical and Molecular Sciences Polytechnic University of the Marche Region Ancona Italy
| | - Claudia Sapigni
- Dermatological Clinic, Department of Clinical and Molecular Sciences Polytechnic University of the Marche Region Ancona Italy
| | - Annamaria Offidani
- Dermatological Clinic, Department of Clinical and Molecular Sciences Polytechnic University of the Marche Region Ancona Italy
| |
Collapse
|
14
|
Giannoni M, Rizzetto G, Sapigni C, Paolinelli M, Tagliati C, Diotallevi F, Campanati A, Mandolesi A, Pepi L, Offidani A. Bullous Sweet's syndrome in a patient with ulcerative colitis: a rare case report. Acta Dermatovenerol Alp Pannonica Adriat 2020; 29:153-155. [PMID: 32975303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Bullous Sweet's syndrome is an uncommon clinical presentation of classical Sweet's syndrome, often associated with various kinds of tumors, infections, and active inflammatory bowel diseases (IBDs), namely Crohn's disease and ulcerative colitis. Only a few cases of bullous Sweet's syndrome associated with ulcerative colitis are described in the literature. We report a case of a 62-year-old female patient with acute exacerbation of ulcerative colitis associated with infiltrating purple-erythematous skin plaques, which were partly vesicular, and oral ulcerative stomatitis. Biopsy was consistent with bullous Sweet's syndrome. Treatment with betamethasone sodium phosphate, starting at 5.5 mg, followed by gradual dose tapering for 12 weeks, resulted in improvement of the ulcerative colitis and disappearance of the cutaneous lesions. Bullous Sweet's syndrome most commonly occurs in the setting of hematologic malignancies, suggesting that physicians should perform long-term screening for early diagnosis of hematological and solid malignancies.
Collapse
Affiliation(s)
- Melania Giannoni
- Department of Clinical and Molecular Sciences, Dermatology Clinic, Polytechnic Marche University, Ancona, Italy
| | - Giulio Rizzetto
- Department of Clinical and Molecular Sciences, Dermatology Clinic, Polytechnic Marche University, Ancona, Italy
| | - Claudia Sapigni
- Department of Clinical and Molecular Sciences, Dermatology Clinic, Polytechnic Marche University, Ancona, Italy
| | - Matteo Paolinelli
- Department of Clinical and Molecular Sciences, Dermatology Clinic, Polytechnic Marche University, Ancona, Italy
| | - Corrado Tagliati
- Department of Clinical and Molecular Sciences, Dermatology Clinic, Polytechnic Marche University, Ancona, Italy
| | - Federico Diotallevi
- Department of Clinical and Molecular Sciences, Dermatology Clinic, Polytechnic Marche University, Ancona, Italy
| | - Anna Campanati
- Department of Clinical and Molecular Sciences, Dermatology Clinic, Polytechnic Marche University, Ancona, Italy
| | - Alessandra Mandolesi
- Department of Experimental and Clinical Medicine, Anatomopathological Institute, Polytechnic Marche University, Ancona, Italy
| | - Laura Pepi
- Department of Experimental and Clinical Medicine, Anatomopathological Institute, Polytechnic Marche University, Ancona, Italy
| | - Annamaria Offidani
- Department of Clinical and Molecular Sciences, Dermatology Clinic, Polytechnic Marche University, Ancona, Italy
| |
Collapse
|
15
|
Campanati A, Brisigotti V, Diotallevi F, D’Agostino G, Paolinelli M, Radi G, Rizzetto G, Sapigni C, Tagliati C, Offidani A. Active implications for dermatologists in 'SARS-CoV-2 ERA': Personal experience and review of literature. J Eur Acad Dermatol Venereol 2020; 34:1626-1632. [PMID: 32426855 PMCID: PMC7276770 DOI: 10.1111/jdv.16646] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2020] [Accepted: 05/11/2020] [Indexed: 01/08/2023]
Abstract
Linked articles: COVID‐19 SPECIAL FORUM. J Eur Acad Dermatol Venereol 2020; 34: e346–e380.
Collapse
Affiliation(s)
- A. Campanati
- Dermatological Clinic Department of Clinical and Molecular SciencesPolytechnic University of the Marche RegionAnconaItaly
| | - V. Brisigotti
- Dermatological Clinic Department of Clinical and Molecular SciencesPolytechnic University of the Marche RegionAnconaItaly
| | - F. Diotallevi
- Dermatological Clinic Department of Clinical and Molecular SciencesPolytechnic University of the Marche RegionAnconaItaly
| | - G.M. D’Agostino
- Dermatological Clinic Department of Clinical and Molecular SciencesPolytechnic University of the Marche RegionAnconaItaly
| | - M. Paolinelli
- Dermatological Clinic Department of Clinical and Molecular SciencesPolytechnic University of the Marche RegionAnconaItaly
| | - G. Radi
- Dermatological Clinic Department of Clinical and Molecular SciencesPolytechnic University of the Marche RegionAnconaItaly
| | - G. Rizzetto
- Dermatological Clinic Department of Clinical and Molecular SciencesPolytechnic University of the Marche RegionAnconaItaly
| | - C. Sapigni
- Dermatological Clinic Department of Clinical and Molecular SciencesPolytechnic University of the Marche RegionAnconaItaly
| | - C. Tagliati
- Dermatological Clinic Department of Clinical and Molecular SciencesPolytechnic University of the Marche RegionAnconaItaly
| | - A. Offidani
- Dermatological Clinic Department of Clinical and Molecular SciencesPolytechnic University of the Marche RegionAnconaItaly
| |
Collapse
|
16
|
Molinelli E, Campanati A, Brisigotti V, Sapigni C, Paolinelli M, Offidani A. Efficacy and Safety of Topical Calcipotriol 0.005% Versus Topical Clobetasol 0.05% in the Management of Alopecia Areata: An Intrasubject Pilot Study. Dermatol Ther (Heidelb) 2020; 10:515-521. [PMID: 32342443 PMCID: PMC7211771 DOI: 10.1007/s13555-020-00379-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2020] [Indexed: 12/31/2022] Open
Abstract
Introduction Alopecia areata (AA) is a chronic inflammatory non-scarring type of hair loss. Current therapies for alopecia areata are rather limited and mainly involve the use of topical, intra-lesional or systemic steroids and topical immunotherapy, with variable benefit. Recent studies have demonstrated that vitamin D analogues could potentially promote hair growth in patients with patchy AA. Methods We investigated the efficacy and safety of treatment with calcipotriol, a synthetic derivative of vitamin D (calcipotriol 0.005% ointment), versus treatment with the corticosteroid clobetasol (topical clobetasol 0.05% formulation), in a series of 35 patients with scalp AA, using an intrasubject design. Results Patches treated with calcipotriol ointment showed greater and faster response rates than did those treated with topical clobetasol, although the differences were not statistically significant. The main strength of the study is its prospective design; the main limitation is the small number of participants. Conclusions Treatment with the calcipotriol would appear to be reasonably effective in patients with mild to moderate patchy AA and was associated with only limited and reversible side effects.
Collapse
Affiliation(s)
- Elisa Molinelli
- Dermatological Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Conca 71 Street, Ancona, Italy.
| | - Anna Campanati
- Dermatological Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Conca 71 Street, Ancona, Italy
| | - Valerio Brisigotti
- Dermatological Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Conca 71 Street, Ancona, Italy
| | - Claudia Sapigni
- Dermatological Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Conca 71 Street, Ancona, Italy
| | - Matteo Paolinelli
- Dermatological Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Conca 71 Street, Ancona, Italy
| | - Annamaria Offidani
- Dermatological Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Conca 71 Street, Ancona, Italy
| |
Collapse
|
17
|
Campanati A, Diotallevi F, Martina E, Paolinelli M, Radi G, Offidani A. Safety update of etanercept treatment for moderate to severe plaque psoriasis. Expert Opin Drug Saf 2020; 19:439-448. [PMID: 32178543 DOI: 10.1080/14740338.2020.1740204] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Introduction: Conventional topical therapies and disease-modifying anti-rheumatic drugs (DMARDs) for patients with psoriasis are often linked to inadequate outcomes and risk of multiple adverse effects. Biologic agents such as etanercept (ETN) have revolutionized the therapeutic management of psoriasis, allowing the treatment of most difficult cases, and fragile patients.Areas covered: The authors searched PubMed using the term 'psoriasis,' 'etanercept,' and 'safety.' Articles considered by the authors to be most relevant, such as randomized controlled studies, cohort studies, and review articles placing emphasis on studies of efficacy and safety were selected. Case reports and letters relating to safety were also included. The main sources of data referenced by these articles were also included in the review. Besides, to get the relevant studies, the reference lists were examined to identify the potentially available studies. The aim of this review is to describe the safety profile of ETN, used for psoriasis treatment, focusing on related clinical implications.Expert opinion: ETN has a favorable safety profile, and its use should be largely considered in psoriatic patients. Caution should be recommended in case of chronic heart failure, autoimmune disease, previous malignancies, familial history of demyelinating diseases, latent TBC infection, chronic HBV and HCV infection or HIV.
Collapse
Affiliation(s)
- Anna Campanati
- Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| | - Federico Diotallevi
- Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| | - Emanuela Martina
- Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| | - Matteo Paolinelli
- Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| | - Giulia Radi
- Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| | - Annamaria Offidani
- Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| |
Collapse
|
18
|
Diotallevi F, Simonetti O, Radi G, Martina E, Paolinelli M, Sapigni C, Guanciarossa F, Bianchelli T, Brancorsini D, Offidani A. Buschke-Ollendorff syndrome in a 6-year-old patient: clinical and histopathological aspects of a rare disease. Acta Dermatovenerol Alp Pannonica Adriat 2020; 29:31-33. [PMID: 32206820] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Buschke-Ollendorff syndrome (BOS) is a rare genetic hereditary genodermatosis characterized by benign skeletal and cutaneous lesions. Skeletal alterations known as osteopoikilosis (OPK) or "spotted bone disease" are asymptomatic areas of sclerosing dysplasia. Two skin lesion patterns have been described because they may be of either elastic tissue (juvenile elastoma) or collagenous composition (dermatofibrosis lenticularis disseminata). We present the case of a 6-year-old male patient with yellowish papules that coalesced to form plaques localized on both thighs and on the upper limbs consistent with a connective tissue nevus (CTN) diagnosis. X-ray examination of the skeletal system revealed the presence of multiple small areas (measuring between 1 and 7 mm) of increased bone density (OPK) bilaterally. A skin biopsy was performed and did not show striking alterations in the number or dimension of the extracellular matrix fibers, but it showed mucin deposition between them, which is compatible with a CTN. This study reports on the clinical presentation and histological examination of this unusual disease.
Collapse
Affiliation(s)
- Federico Diotallevi
- Department of Clinical and Molecular Sciences, Dermatological clinic, Polytechnic University of the Marche Region, Ancona, Italy
| | - Oriana Simonetti
- Department of Clinical and Molecular Sciences, Dermatological clinic, Polytechnic University of the Marche Region, Ancona, Italy
| | - Giulia Radi
- Department of Clinical and Molecular Sciences, Dermatological clinic, Polytechnic University of the Marche Region, Ancona, Italy
| | - Emanuela Martina
- Department of Clinical and Molecular Sciences, Dermatological clinic, Polytechnic University of the Marche Region, Ancona, Italy
| | - Matteo Paolinelli
- Department of Clinical and Molecular Sciences, Dermatological clinic, Polytechnic University of the Marche Region, Ancona, Italy
| | - Claudia Sapigni
- Department of Clinical and Molecular Sciences, Dermatological clinic, Polytechnic University of the Marche Region, Ancona, Italy
| | - Francesca Guanciarossa
- Department of Clinical and Molecular Sciences, Dermatological clinic, Polytechnic University of the Marche Region, Ancona, Italy
| | - Tommaso Bianchelli
- Department of Clinical and Molecular Sciences, Dermatological clinic, Polytechnic University of the Marche Region, Ancona, Italy
| | - Donatella Brancorsini
- Institute of Pathological Anatomy and Histopathology, Polytechnic University of the Marche Region, Ancona, Italy
| | - Annamaria Offidani
- Department of Clinical and Molecular Sciences, Dermatological clinic, Polytechnic University of the Marche Region, Ancona, Italy
| |
Collapse
|
19
|
Diotallevi F, Simonetti O, Radi G, Martina E, Paolinelli M, Sapigni C, Guanciarossa F, Bianchelli T, Brancorsini D, Offidani A. Buschke–Ollendorff syndrome in a 6-year-old patient: clinical and histopathological aspects of a rare disease. Acta Dermatovenerologica Alpina Pannonica et Adriatica 2020. [DOI: 10.15570/actaapa.2020.7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
20
|
Campanati A, Paolinelli M, Diotallevi F, Martina E, Molinelli E, Offidani A. Pharmacodynamics OF TNF α inhibitors for the treatment of psoriasis. Expert Opin Drug Metab Toxicol 2019; 15:913-925. [PMID: 31623470 DOI: 10.1080/17425255.2019.1681969] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Introduction: The treatment of psoriasis with conventional topical therapies and disease-modifying anti-rheumatic drugs (DMARDs) is often linked to unsatisfactory outcomes and the risk of serious adverse events. Over the last decades, research advances in understanding the role of tumor necrosis factor alpha (TNF α) and other cytokines in the pathogenesis of psoriasis have driven the introduction of biologic agents targeting specific immune mediators in everyday clinical practice. TNF α inhibitors are a consolidated treatment option for patients with moderate-to-severe disease with remarkable efficacy and a reassuring safety profile.Areas covered: The PubMed database was searched using combinations of the following keywords: psoriasis, TNF α inhibitors, biologic therapy, pharmacodynamics, adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, adverse effects. The aim of this review is to describe the pharmacodynamic profile of anti-TNF α inhibitors, currently approved by the European Medicines Agency (EMA) for the treatment of psoriasis, focusing on related clinical implications, also in comparison to the new generation biological therapies targeting the interleukin 23/interleukin 17 axis.Expert opinion: Pharmacodynamics of TNF α inhibitors should be fully considered in planning patient's therapy strategies, especially in case of secondary failures, poor adherence to treatment, instable psoriasis, high risk of infection, pregnant or lactating women, metabolic comorbidities, coexistence of other immune-mediated inflammatory diseases.
Collapse
Affiliation(s)
- Anna Campanati
- Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| | - Matteo Paolinelli
- Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| | - Frederico Diotallevi
- Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| | - Emanuela Martina
- Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| | - Elisa Molinelli
- Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| | - Annamaria Offidani
- Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| |
Collapse
|
21
|
Molinelli E, Paolinelli M, Campanati A, Brisigotti V, Offidani A. Metabolic, pharmacokinetic, and toxicological issues surrounding dapsone. Expert Opin Drug Metab Toxicol 2019; 15:367-379. [DOI: 10.1080/17425255.2019.1600670] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- Elisa Molinelli
- Dermatological Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| | - Matteo Paolinelli
- Dermatological Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| | - Anna Campanati
- Dermatological Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| | - Valerio Brisigotti
- Dermatological Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| | - Annamaria Offidani
- Dermatological Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
| |
Collapse
|